Yahoo Finance

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the broader pharmaceutical industry. “We don’t believe tariffs are the right mechanism” to bolster U.S. drug manufacturing, Lilly Chief Executive David Ricks said on a conference call with analysts Thursday. “The announced tariffs currently in effect do not materially change Lilly’s 2025 financial outlook,” he said.